In this investing video, Owain Bennallack explains why he believes that AstraZeneca’s (LSE: AZN) (NYSE: AZN.US) statement that it expects to maintain 2013’s level of revenues to 2017 isn’t as downbeat as investors may initially think, and why both Astra and GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) are coming back into favour…
AstraZeneca Plc Confident Over Revenues Until 2017
VIDEO: One Fool puts AstraZeneca plc (LON:AZN) under the spotlight, and compares it with GlaxoSmithKline plc (LON:GSK).
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.